Money Control

Money Control
Share

Money Control

 •  October 5

Indian drug makers’ revenue growth in US may cool off to 7-10 percent over the next three years after mid- to high double-digit growth over the last five years owing to rising competition. Moneycontrol News Indian drug makers’ revenue growth in US may cool off to 7-10 percent over the next three years after mid- to high double-digit growth over the...

Money Control

 •  July 14

Moneycontrol News Biocon's shares added over 9 percent intraday on Friday as investors cheered the possible regulatory approval to its breast cancer biosimilar going forward. The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended an approval of the Mylan and Biocon’s proposed biosimilar trastuzumab,...

Money Control

 •  May 27

The raids were carried out at the company premises in Vile Parle (East) and at their godowns at Prerana Complex, Anjur Road, Bhiwandi, in Thane district. Maharashtra's Food and Drug Administration (FDA) seized illegal drugs worth Rs 40 lakh during raids at premises of Pioma Chemicals in Mumbai and Thane. The raids were carried out at the company...

Money Control

 •  March 29

Indian drugmaker Biocon has partnered with Japanese drug firm Eisai Pharma to market the latter's anti-ulcer drug rabeprazole in India. Eisai’s brand is sold as Parit and its combination drug Parit-D. The Japanese firm has terminated its earlier co-marketing arrangement with GSK in India, with sources saying Eisai was disappointed with its...

Money Control

 •  March 8

Drug major Glenmark today said the US health regulator has cleared its investigational new drug (IND) application to begin a phase two study of GSP 304 to be used for treatment of a respiratory disease. "The US Food and Drug Administration (FDA) cleared the company's investigational new drug (IND) application to begin a phase two study of GSP 304...